SEHK:1875

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

HK$2.6b

Last Updated

2021/06/18 10:19 UTC

Data Sources

Company Financials +

Executive Summary

TOT BIOPHARM International Company Limited, an investment holding company, engages in the research and development, manufacture, and marketing of anti-tumor drugs in the People’s Republic of China. More Details


Snowflake Analysis

Adequate balance sheet and fair value.

Share Price & News

How has TOT BIOPHARM International's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1875 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 1875's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

-4.0%

1875

-4.6%

HK Biotechs

-1.5%

HK Market


1 Year Return

-12.4%

1875

42.8%

HK Biotechs

21.7%

HK Market

Return vs Industry: 1875 underperformed the Hong Kong Biotechs industry which returned 42.8% over the past year.

Return vs Market: 1875 underperformed the Hong Kong Market which returned 21.7% over the past year.


Shareholder returns

1875IndustryMarket
7 Day-4.0%-4.6%-1.5%
30 Day-2.5%3.7%-0.9%
90 Day-1.4%12.7%-2.5%
1 Year-12.4%-12.4%43.0%42.8%26.2%21.7%
3 Yearn/a-10.4%-11.8%9.7%-1.9%
5 Yearn/a65.9%60.0%56.3%29.7%

Long-Term Price Volatility Vs. Market

How volatile is TOT BIOPHARM International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is TOT BIOPHARM International undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1875 (HK$4.37) is trading below our estimate of fair value (HK$9.53)

Significantly Below Fair Value: 1875 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 1875 is unprofitable, so we can't compare its PE Ratio to the Hong Kong Biotechs industry average.

PE vs Market: 1875 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1875's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1875 is good value based on its PB Ratio (3.7x) compared to the HK Biotechs industry average (4.1x).


Future Growth

How is TOT BIOPHARM International forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

34.7%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1875's forecast earnings growth is above the savings rate (1.5%).

Earnings vs Market: Insufficient data to determine if 1875's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 1875's revenue (34.7% per year) is forecast to grow faster than the Hong Kong market (12.6% per year).

High Growth Revenue: 1875's revenue (34.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1875's Return on Equity is forecast to be high in 3 years time (26.6%)


Past Performance

How has TOT BIOPHARM International performed over the past 5 years?

3.6%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: 1875 is currently unprofitable.

Growing Profit Margin: 1875 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 1875's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 1875's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1875 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (43.1%).


Return on Equity

High ROE: 1875 has a negative Return on Equity (-49.54%), as it is currently unprofitable.


Financial Health

How is TOT BIOPHARM International's financial position?


Financial Position Analysis

Short Term Liabilities: 1875's short term assets (CN¥249.2M) exceed its short term liabilities (CN¥52.7M).

Long Term Liabilities: 1875's short term assets (CN¥249.2M) exceed its long term liabilities (CN¥6.1M).


Debt to Equity History and Analysis

Debt Level: 1875 is debt free.

Reducing Debt: 1875 had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1875 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 1875 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 4.8% each year


Dividend

What is TOT BIOPHARM International current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1875's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1875's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1875's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1875's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1875's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Jun Liu (52 yo)

0.67

Tenure

Dr. Jun Liu serves as Chief Executive Officer at TOT BIOPHARM International Company Limited since October 15, 2020 and serves as its Executive Director since October 26, 2018. Dr. Liu serves as Chief Scien...


Leadership Team

Experienced Management: 1875's management team is considered experienced (3 years average tenure).


Board Members

Experienced Board: 1875's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.5%.


Top Shareholders

Company Information

TOT BIOPHARM International Company Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: TOT BIOPHARM International Company Limited
  • Ticker: 1875
  • Exchange: SEHK
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$2.629b
  • Shares outstanding: 601.53m
  • Website: https://www.totbiopharm.com

Number of Employees


Location

  • TOT BIOPHARM International Company Limited
  • No. 120 Changyang Street
  • Suzhou Industrial Park
  • Suzhou
  • Jiangsu Province
  • 215024
  • China

Listings


Biography

TOT BIOPHARM International Company Limited, an investment holding company, engages in the research and development, manufacture, and marketing of anti-tumor drugs in the People’s Republic of China. Its pri...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/18 10:19
End of Day Share Price2021/06/18 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.